Lumos Pharma (stock symbol: LUMO) Logo in transparent PNG and SVG formats

About Lumos Pharma

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

• Website domain: lumos-pharma.com
• Employees: 32
• Marketcap: $27.45 Million USD